The association between stent type and developing angina pectoris following percutaneous coronary intervention.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 14 03 2024
accepted: 12 08 2024
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 1 9 2024
Statut: epublish

Résumé

Angina pectoris can occur in up to 40% of patients following percutaneous coronary intervention (PCI). There is limited data assessing whether the type of stent implanted during revascularization can predict post-PCI angina symptoms. In this study, data regarding revascularization characteristics including the stent type in patients admitted for PCI was collected. Prospective data including occurrence of angina and the presenting class, new onset ST-segment elevation myocardial infarction (STEMI), and other clinical outcomes were collected at 1, 3, and 6-month follow-up intervals. Univariable and multivariable logistic regression models were used to assess the potential predictors of angina symptoms at 6-month follow-up. A total of 787 patients (64.5% males) undergoing PCI with three stent types (Orsiro, Promus, and Xience) were included in the study. The occurrence of post PCI angina pectoris and new STEMI was similar among the stent types (p > 0.05). A linear association was found between the development of new STEMI (p = 0.018) and stroke (p = 0.003) and the worsening of angina class. The stent type was not a predictor of angina during the follow-up period. Other variables including dyslipidemia (odds ratio (OR) (95% CI), 1.51 (1.08; 2.10)), prior coronary artery disease (CAD) (OR (95% CI), 1.63 (1.02; 2.61)), and previous hospitalization (OR (95% CI), 2.10 (1.22; 3.63)) were independent predictors of angina. Although the type of stent may not have an association with the post-PCI angina, other predictors such as dyslipidemia and previous CAD and hospitalization may predict recurrence of cardiac angina. The class of angina severity may have a linear association with new-onset STEMI and stroke.

Sections du résumé

BACKGROUND BACKGROUND
Angina pectoris can occur in up to 40% of patients following percutaneous coronary intervention (PCI). There is limited data assessing whether the type of stent implanted during revascularization can predict post-PCI angina symptoms.
METHODS METHODS
In this study, data regarding revascularization characteristics including the stent type in patients admitted for PCI was collected. Prospective data including occurrence of angina and the presenting class, new onset ST-segment elevation myocardial infarction (STEMI), and other clinical outcomes were collected at 1, 3, and 6-month follow-up intervals. Univariable and multivariable logistic regression models were used to assess the potential predictors of angina symptoms at 6-month follow-up.
RESULTS RESULTS
A total of 787 patients (64.5% males) undergoing PCI with three stent types (Orsiro, Promus, and Xience) were included in the study. The occurrence of post PCI angina pectoris and new STEMI was similar among the stent types (p > 0.05). A linear association was found between the development of new STEMI (p = 0.018) and stroke (p = 0.003) and the worsening of angina class. The stent type was not a predictor of angina during the follow-up period. Other variables including dyslipidemia (odds ratio (OR) (95% CI), 1.51 (1.08; 2.10)), prior coronary artery disease (CAD) (OR (95% CI), 1.63 (1.02; 2.61)), and previous hospitalization (OR (95% CI), 2.10 (1.22; 3.63)) were independent predictors of angina.
CONCLUSIONS CONCLUSIONS
Although the type of stent may not have an association with the post-PCI angina, other predictors such as dyslipidemia and previous CAD and hospitalization may predict recurrence of cardiac angina. The class of angina severity may have a linear association with new-onset STEMI and stroke.

Identifiants

pubmed: 39218866
doi: 10.1186/s12872-024-04116-2
pii: 10.1186/s12872-024-04116-2
doi:

Types de publication

Journal Article Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

466

Informations de copyright

© 2024. The Author(s).

Références

Throndson K, Sawatzky JA. Angina following percutaneous coronary intervention: in-stent restenosis. Can J Cardiovasc Nurs. 2009;19(3):16–23.
pubmed: 19694113
Ajmal M, Chatterjee A, Acharya D. Persistent or recurrent Angina following percutaneous coronary revascularization. Curr Cardiol Rep. 2022;24(12):1837–48.
doi: 10.1007/s11886-022-01820-3 pubmed: 36287295
Niccoli G, Montone RA, Lanza GA, Crea F. Angina after percutaneous coronary intervention: the need for precision medicine. Int J Cardiol. 2017;248:14–9.
doi: 10.1016/j.ijcard.2017.07.105 pubmed: 28807510
Abbate A, Biondi-Zoccai GG, Agostoni P, Lipinski MJ, Vetrovec GW. Recurrent angina after coronary revascularization: a clinical challenge. Eur Heart J. 2007;28(9):1057–65.
doi: 10.1093/eurheartj/ehl562 pubmed: 17384090
Blumenthal DM, Howard SE, Searl Como J, O’Keefe SM, Atlas SJ, Horn DM, et al. Prevalence of Angina among Primary Care patients with coronary artery disease. JAMA Netw Open. 2021;4(6):e2112800.
doi: 10.1001/jamanetworkopen.2021.12800 pubmed: 34097047 pmcid: 8185599
Verreault-Julien L, Bhatt DL, Jung RG, Di Santo P, Simard T, Avram R, et al. Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coron Artery Dis. 2022;33(2):98–104.
doi: 10.1097/MCA.0000000000001081 pubmed: 34148973
Taglieri N, Bruno AG, Ghetti G, Marrozzini C, Saia F, Galié N, et al. Target lesion failure with current drug-eluting stents: evidence from a Comprehensive Network Meta-Analysis. JACC Cardiovasc Interv. 2020;13(24):2868–78.
doi: 10.1016/j.jcin.2020.09.014 pubmed: 33357524
Gaglia MA Jr., Torguson R, Lipinski MJ, Gai J, Koifman E, Kiramijyan S, et al. Frequency of Angina Pectoris after Percutaneous Coronary intervention and the effect of metallic stent type. Am J Cardiol. 2016;117(4):526–31.
doi: 10.1016/j.amjcard.2015.11.036 pubmed: 26739394
Olivier J, May WL, Bell ML. Relative effect sizes for measures of risk. Commun Stat - Theory Methods. 2017;46(14):6774–81.
doi: 10.1080/03610926.2015.1134575
Schopfer DW, Beatty AL, Meyer CS, Whooley MA. Longitudinal Association between Angina Pectoris and Quality of Life. Am J Cardiol. 2022;164:1–6.
doi: 10.1016/j.amjcard.2021.10.037 pubmed: 34838288
Spoletini I, Ferrari R, Rosano GMC. Living with stable angina: patients’ pathway and needs in angina. J Cardiovasc Med (Hagerstown). 2020;21(5):377–82.
doi: 10.2459/JCM.0000000000000954 pubmed: 32205502
Collison D, Copt S, Mizukami T, Collet C, McLaren R, Didagelos M, et al. Angina after Percutaneous Coronary intervention: patient and procedural predictors. Circ Cardiovasc Interv. 2023;16(4):e012511.
doi: 10.1161/CIRCINTERVENTIONS.122.012511 pubmed: 36974680 pmcid: 10101135
Crea F, Bairey Merz CN, Beltrame JF, Berry C, Camici PG, Kaski JC, et al. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 2019;40(29):2455–62.
doi: 10.1093/eurheartj/ehy857 pubmed: 30608528
De Luca L, Rosano GMC, Spoletini I. Post-percutaneous coronary intervention angina: from physiopathological mechanisms to individualized treatment. Cardiol J. 2022;29(5):850–7.
doi: 10.5603/CJ.a2021.0042 pubmed: 33843042 pmcid: 9550331
Xu K, Jiang Y, Yang W, Zhang W, Wang D, Zhao Y, et al. Post-procedural and long-term functional outcomes of jailed side branches in stented coronary bifurcation lesions assessed with side branch Murray law-based quantitative flow ratio. Front Cardiovasc Med. 2023;10:1217069.
doi: 10.3389/fcvm.2023.1217069 pubmed: 37600052 pmcid: 10435891
Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530–40.
doi: 10.1016/S0140-6736(18)32283-9 pubmed: 30266412
Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, et al. Drug-eluting or Bare-Metal stents for Coronary Artery Disease. N Engl J Med. 2016;375(13):1242–52.
doi: 10.1056/NEJMoa1607991 pubmed: 27572953
Bonaventura A, Montecucco F, Liberale L. Coronary stenting: A matter of revascularization. World J Cardiol. 2017;9(3):207–11.
doi: 10.4330/wjc.v9.i3.207 pubmed: 28400917 pmcid: 5368670
Lardizabal JA, Deedwania PC. The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep. 2011;13(1):43–50.
doi: 10.1007/s11883-010-0147-y pubmed: 21107759
Deanfield JE, Sellier P, Thaulow E, Bultas J, Yunis C, Shi H, et al. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Heart J. 2010;31(21):2650–9.
doi: 10.1093/eurheartj/ehq133 pubmed: 20494902 pmcid: 2966969
Tanne D, Shotan A, Goldbourt U, Haim M, Boyko V, Adler Y, et al. Severity of angina pectoris and risk of ischemic stroke. Stroke. 2002;33(1):245–50.
doi: 10.1161/hs0102.101630 pubmed: 11779917

Auteurs

Amirali Nejat (A)

Department of Cardiovascular Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Alireza Hosseinpour (A)

Department of Cardiovascular Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Alireza.hosseinpour1997@gmail.com.
School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Alireza.hosseinpour1997@gmail.com.

Pouria Azami (P)

Department of Cardiovascular Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Kasra Assadian (K)

School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Armin Attar (A)

Department of Cardiovascular Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Peyman Izadpanah (P)

Department of Cardiovascular Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. izadpanahpeyman52@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH